Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jake Baum

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
ACS Infectious Diseases|April 30, 2021
Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as <i>Plasmodium</i> Cytoplasmic Prolyl-tRNA Synthetase InhibitorsMasanori Okaniwa, Akira Shibata, Atsuko Ochida, et al.
Immunity|April 10, 2012
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filamentsJian-Guo Zhang, Peter E Czabotar, Antonia N Policheni, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Journal of Medicinal Chemistry|September 18, 2020
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridinesScott Eagon, Jared T Hammill, Martina Sigal, et al.
European Journal of Medicinal Chemistry|October 10, 2024
Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome bJon Kyle Awalt, Wenyin Su, William Nguyen, et al.
ACS Infectious Diseases|November 11, 2024
Tambjamines as Fast-Acting Multistage AntimalarialsAmrendra Kumar, Yuexin Li, Rozalia A Dodean, et al.
Science (New York, N.Y.)|June 2, 2022
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategyStanley C Xie, Riley D Metcalfe, Elyse Dunn, et al.
Journal of Medicinal Chemistry|April 14, 2025
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4Jon Kyle Awalt, Zi Kang Ooi, Trent D Ashton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2021
Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasomeStanley C Xie, Riley D Metcalfe, Hirotake Mizutani, et al.
Nature Communications|April 21, 2022
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183Laura E de Vries, Patrick A M Jansen, Catalina Barcelo, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
ACS Infectious Diseases|April 30, 2021
Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as <i>Plasmodium</i> Cytoplasmic Prolyl-tRNA Synthetase InhibitorsMasanori Okaniwa, Akira Shibata, Atsuko Ochida, et al.
Immunity|April 10, 2012
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filamentsJian-Guo Zhang, Peter E Czabotar, Antonia N Policheni, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Journal of Medicinal Chemistry|September 18, 2020
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridinesScott Eagon, Jared T Hammill, Martina Sigal, et al.
European Journal of Medicinal Chemistry|October 10, 2024
Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome bJon Kyle Awalt, Wenyin Su, William Nguyen, et al.
ACS Infectious Diseases|November 11, 2024
Tambjamines as Fast-Acting Multistage AntimalarialsAmrendra Kumar, Yuexin Li, Rozalia A Dodean, et al.
Science (New York, N.Y.)|June 2, 2022
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategyStanley C Xie, Riley D Metcalfe, Elyse Dunn, et al.
Journal of Medicinal Chemistry|April 14, 2025
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4Jon Kyle Awalt, Zi Kang Ooi, Trent D Ashton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2021
Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasomeStanley C Xie, Riley D Metcalfe, Hirotake Mizutani, et al.
Nature Communications|April 21, 2022
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183Laura E de Vries, Patrick A M Jansen, Catalina Barcelo, et al.
Pageof 14